#esmo2025 hashtag - Bluesky

Dr Barbara Burtness's Key Takeaways in Head and Neck Cancer from ESMO Congress 2025 Barbara Burtness, MD highlights key news in head and neck cancer from ESMO 2025, including CAMORAL, ASPEN-03 & -04, OrigAMI-4 & -05 results.

4 months ago

Dr Burtness shares some of her key takeaways in #headandNeckCancer from @myesmo.bsky.social #ESMO2025.

https://bit.ly/48j1vTk

#hncsm #HNC

0 0 0 0

ECOG-ACRIN Cancer Research Group

@eaonc.bsky.social

4 months ago

SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade - Nature mRNA vaccines targeting SARS-CoV-2 also sensitize tumours to immune checkpoint inhibitors.

ICYMI, fascinating finding from #ESMO2025: patients with #cancer who received mRNA COVID vaccines soon after starting #immunotherapy showed stronger immune responses & improved survival. Read the the publication in @nature.com: bit.ly/3LyoZuF #CancerResearch

0 0 0 0

Lumanity

@lumanity.bsky.social

4 months ago

#ESMO2025 was a reminder of how quickly oncology is evolving, from practice-changing #ADC data in breast and bladder #cancer, to novel #immunotherapy combinations in lung cancer, and a renewed focus on #QualityOfLife. Read on: buff.ly/JNLCKcf

#Oncology #CancerResearch

0 0 0 0

40:40 Recruitment - celia@4040recruitment.co.uk

@4040rec.bsky.social

4 months ago

5 clinical advances and related implications from ESMO 2025 5 particularly insightful takeaways from this year’s ESMO Congress that merit deeper reflection on where cancer care can go.

#Oncology #ESMO2025 #EuropeanSocietyforMedicalOncology #ADCs #immunotherapy #precisiononcology #oncologydrugdevelopment #biomarkers #oncologyinnovation #biotech #pharmaceuticals #oncologytrialplanning #molecularprecisiononcology #preclinicaloncologyresearch #oncologydrugdevelopment
zurl.co/YwBWP

0 0 0 0

4 months ago

esmo

[Spécial #ESMO2025]
Consultez notre page dédiée au congrès européen d'oncologie médicale !
ms.spr.ly/63321tJUol

0 0 0 0

Mélanome : ajouter un vaccin au pembrolizumab n'améliore pas la survie sans progression Une étude suggère que les patients atteints d'un mélanome avancé non traité ne semblent pas bénéficier d'un avantage en termes de survie sans progression lorsque le vaccin IO102-IO103 est ajouté au pembrolizumab.

4 months ago

Mélanome : ajouter un vaccin au pembrolizumab n'améliore pas la survie sans progression
#ESMO2025
ms.spr.ly/63329tJziv

0 0 0 0

National Centre for Asbestos Related Diseases

4 months ago

From #ESMO2025 - Prof. Christof Vulsteke shares study findings that position perioperative enfortumab vedotin plus #pembrolizumab as a new option for cisplatin-ineligible muscle-invasive #BladderCancer.

Watch the full interview 👉 buff.ly/RNdTu6h

#OncSky #MedNews

0 0 0 0

@ncard-research.bsky.social

5 months ago

ESMO® 2025 Highlights: Presenter Vignette - Anna Nowak - OncologyEducation Primary results of DREAM3R: DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma – A phase 3 Randomised trial

Professor Anna Nowak presented DREAM3R trial results at ESMO Congress 2025 in Berlin - investigating durvalumab + chemo for advanced pleural #mesothelioma. A major step forward in Phase III research.

Watch highlights →
www.oncologyeducation.com/videos/esmo-...

#ESMO2025 #NCARDresearch

1 0 0 0

OncLive

@onclive.bsky.social

5 months ago

Adjuvant Durvalumab Plus Tremelimumab Yields DFS Advantage in Resected RCC | OncLive Treatment with adjuvant durvalumab plus tremelimumab resulted in a DFS benefit vs active monitoring in RCC, particularly in the higher-risk population.

Adjuvant Durvalumab Plus Tremelimumab Yields DFS Advantage in Resected RCC @myesmo.bsky.social #ESMO2025 #ESMO25 #kcsm #oncology
www.onclive.com/view/adjuvan...

1 0 0 0

Novel T-cell therapy shows promise in uveal melanoma The PRAME-directed T-cell receptor T-cell therapy anzutresgene autoleucel has shown encouraging tolerability and antitumor activity in uveal melanoma.

5 months ago

From #ESMO2025 - The PRAME-directed T-cell receptor T-cell therapy anzutresgene autoleucel has shown encouraging tolerability and antitumor activity in uveal melanoma.

Full story 👉 buff.ly/GZ4bZkz

#OncSky #EyeSky

0 0 0 0

Innovations thérapeutiques dans le mélanome uvéal À l'ESMO 2025, des données prometteuses pourraient redéfinir la prise en charge du mélanome uvéal : inhibiteur de PKC, combinaison pembrolizumab + lenvatinib, approches hépatiques, récepteur de cellules T anti-PRAME...

5 months ago

Innovations thérapeutiques dans le mélanome uvéal
À l’#ESMO2025, des données prometteuses pourraient redéfinir la prise en charge du mélanome uvéal. Explications de Manuel Rodrigues et Diana Bello Roufai
ms.spr.ly/63322ty6fG

1 0 0 0

OncLive

@onclive.bsky.social

5 months ago

177Lu-Edotreotide Demonstrates Efficacy and Notable Safety Advantage in Advanced GEP-NETs | OncLive Jaume Capdevila, MD, PhD, discusses the potential for 177Lu-edotreotide for the treatment of patients with neuroendocrine tumors.

177Lu-Edotreotide Demonstrates Efficacy and Notable Safety Advantage in Advanced GEP-NETs @vhio.bsky.social @vallhebron.com @myesmo.bsky.social #ESMO25 #ESMO2025 #Oncology
www.onclive.com/view/177lu-e...

1 1 0 0

5 months ago

From #ESMO2025 - Dr. Erica Mayer highlights the benefit of treatment with #giredestrant plus #everolimus in patients with ER-positive, HER2-negative advanced #BreastCancer who have previously received a CDK4/6 inhibitor.

Watch now 👉 buff.ly/D0apqEh

#MedNews #OncSky

0 0 0 0

T-DXd Bests T-DM1 in HER2+ Early Breast Cancer Adjuvant T-DXd can improve outcomes vs T-DM1 in patients with high-risk, HER2+ early breast cancer and residual invasive disease, data suggest.

5 months ago

Adjuvant T-DXd can improve outcomes when compared to T-DM1 in patients with high-risk, HER2-positive early #breastcancer who have residual invasive disease. Presented at #ESMO2025.

https://bit.ly/4hAhkIk

#bcsm #ESMO25

0 0 0 0

5 months ago

From #ESMO2025 - Prof. Jeanne Tie explains why ctDNA-guided treatment de-escalation could be considered in certain patients with #ColonCancer despite the trial not meeting its primary endpoint.

Watch the full interview 👉 buff.ly/EZ6gTh6

#OncSky #MedNews

0 0 0 0

Cancer du poumon : des nouveautés qui révolutionnent les traitements Tour d’horizon des études qui ont marqué l’ESMO 2025 en oncologie thoracique : ivonescimab, sac TMT, tarlatamab et plus… Avec Marie Wislez et Nicolas Girard

5 months ago

Cancer du poumon : des nouveautés qui révolutionnent les traitements
Tour d’horizon des études qui ont marqué l’#ESMO2025 en oncologie thoracique : ivonescimab, sac TMT, tarlatamab et plus… Avec Marie Wislez et Nicolas Girard
ms.spr.ly/63323tDUEd

1 0 0 0

K.I.T. Group

@kitgroup.bsky.social

5 months ago

From 17–21 Oct, the global oncology community gathered in Berlin at #ESMO2025. As the official accommodation partner, K.I.T. Group proudly supported 37,000+ participants — ensuring a seamless experience.
Teamwork, flexibility & great partners, that’s how event magic happens!

0 0 0 0

Novel ADC Outperforms Chemotherapy in EGFR-Mutated NSCLC Survival OptiTROP-Lung04 study showed sac-TMT improved survival in pts with EGFR-mutated NSCLC who had progressed on EGFR-targeted TKIs, compared with chemotherapy.

5 months ago

The TROP2 ADC sac-TMT improved survival, compared with platinum-based chemotherapy, in patients with EGFR-mutated NSCLC who had progressed on EGFR-targeted TKIs. Presented at #ESMO25.

https://bit.ly/3LeE8Bl

#lcsm #ESMO2025

1 0 0 0

Craig Underhill MBBS FRACP

@craigunderhill.bsky.social

5 months ago

It’s so hard keeping Christopher Jackson & @drkiwikate.bsky.social on track from over here in far west New Zealand but as usual, we somehow manage to mix the latest info with a few laughs, covering ESMO Berlin. Enjoy and look out for part 2, out soon.
#medsky #oncsky #onced #ojc #oncology #esmo2025

0 0 0 0

ESMO - European Society for Medical Oncology

@myesmo.bsky.social

5 months ago

🚨 Registration is open! Join global experts for the #ESMO25 Congress Highlights Webinar on Breast & Gynaecological Cancers.
🔗 Register now with your ESMO account: https://ow.ly/9lZi50XiUpN

#Oncology #BreastCancer #GynaeCancer #ESMO2025

2 0 0 0

The Oncology Network

@theoncologynetwork.bsky.social

5 months ago

NEW PODCAST: Grab your coffee and your bingo card (yes, it's downloadable so you can play along!)☕🎲
It’s ESMO Oncology Journal Club time! Part 1 t.ly/hk8pe
@craigunderhill.bsky.social, @drkiwikate.bsky.social & Christopher Jackson break down the abstracts from #ESMO2025
#OJC #MedEd #OncologyPodcast

3 1 0 1

T-DXd Bests T-DM1 in HER2+ Early Breast Cancer Adjuvant T-DXd can improve outcomes vs T-DM1 in patients with high-risk, HER2+ early breast cancer and residual invasive disease, data suggest.

5 months ago

Adjuvant T-DXd can improve outcomes when compared to T-DM1 in patients with high-risk, HER2-positive early #breastcancer who have residual invasive disease. Presented at #ESMO2025.

https://bit.ly/4hAhkIk

#bcsm #BCAM #BreastCancerAwarenessMonth

0 0 0 0

Vall d’Hebron Institute of Oncology

@vhio.bsky.social

5 months ago

👨‍⚕️ El Dr. Pau Mascaró, R5 de #OncologíaMédica en @vallhebron.com‬ – VHIO, presentó en @myESMO una comunicación oral y un póster, un logro excepcional durante la residencia.

🔗 Descubre su experiencia 👉 https://resisoncovh.com/pau-mascaro-esmo-2025/

#ESMO2025 #ResisOncoVH

1 0 0 0